GPCR/G protein


All GPCRs share a common seven trans-membrane structure. GPCRs are associated with heterotrimeric G-proteins which are GTP-binding proteins made of alpha, beta, and gamma subunits. When a ligand binds to GPCR, it activates the attached G-protein, the GDP is replaced with GTP. The activated G-protein then dissociates into an alpha and a beta-gamma complex which activates downstream signaling pathways. These intracellular signaling pathways include cAMP/PKA, calcium/NFAT, phospholipase C, protein tyrosine kinases, MAP kinases, PI-3-kinase, nitric oxide/cGMP, Rho, and JAK/STAT.
GPCRs are one of the most important therapeutic targets for various diseases, over 30% of all modern medicinal drugs target this family. Aberrant GPCR functions are involved in pathological conditions such as neurological, immunological and hormonal disorders. A large number of GPCRs have been identified, but whose ligands are not known, are classified as orphan receptors.
-
B2085 CCG 50014Target: RGSSummary: RGS4 Inhibitor,potent and selective -
B1713 Clorprenaline HCLSummary: Adrenergic receptor agonist -
B2236 DesvenlafaxineTarget: 5-HT Transporters|Norepinephrine transportersSummary: serotonin (5-HT) and norepinephrine (NE) reuptake inhibitor -
B2246 Desvenlafaxine SuccinateSummary: serotonin (5-HT) transporter and norepinephrine (NE) transporter reuptake inhibitor -
B1734 DoxofyllineSummary: PDE inhibitor -
B1735 Doxylamine SuccinateSummary: Histamine receptor inhibitor -
B1738 DroxidopaTarget: adrenergic receptorSummary: Adrenergic receptor agonist -
B1744 Epinastine HClTarget: Histamine H1 ReceptorsSummary: Histamine receptor antagonist -
B1327 Epinephrine HClSummary: Adrenergic receptor agonist -
B1745 Eprazinone 2HClSummary: Aucolytic

